Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders

Massimiliano Ruscica, Sara Simonelli, Margherita Botta, Alice Ossoli, Maria Giovanna Lupo, Paolo Magni, Alberto Corsini, Marcello Arca, Livia Pisciotta, Fabrizio Veglia, Guido Franceschini, Nicola Ferri, Laura Calabresi

Research output: Contribution to journalArticle

Abstract

Proprotein convertase subtilisin/kexin 9 (PCSK9), a protein regulating the number of cell-surface LDL receptors (LDLR), circulates partially associated to plasma lipoproteins. How this interaction alters PCSK9 plasma levels is still unclear. In the present study, we took advantage of the availability of a large cohort of carriers of genetic HDL disorders to evaluate how HDL defects affect plasma PCSK9 levels and its distribution among lipoproteins. Plasma PCSK9 concentrations were determined by ELISA in carriers of mutations in LCAT, ABCA1, or APOAI genes, and lipoprotein distribution was analyzed by FPLC. Carriers of one or two mutations in the LCAT gene show plasma PCSK9 levels comparable to that of unaffected family controls (homozygotes, 159.4 ng/mL (124.9;243.3); heterozygotes, 180.3 ng/mL (127.6;251.5) and controls, 190.4 ng/mL (146.7;264.4); P for trend = 0.33). Measurement of PCSK9 in plasma of subjects carrying mutations in ABCA1 or APOAI genes confirmed normal values. When fractionated by FPLC, PCSK9 peaked in a region between LDL and HDL in control subjects. In carriers of all HDL defects, lipoprotein profile shows a strong reduction of HDL, but the distribution of PCSK9 was superimposable to that of controls. In conclusion, the present study demonstrates that in genetically determined low HDL states plasma PCSK9 concentrations and lipoprotein distribution are preserved, thus suggesting that HDL may not be involved in PCSK9 transport in plasma.

Original languageEnglish
Pages (from-to)991-997
Number of pages7
JournalBiochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Volume1863
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Proprotein Convertases
Subtilisin
Inborn Genetic Diseases
Lipoproteins
Mutation
Genes
LDL Receptors
Homozygote
Cell Surface Receptors
HDL Lipoproteins
Heterozygote
Reference Values
Enzyme-Linked Immunosorbent Assay

Keywords

  • Genetic HDL disorders
  • High-density lipoproteins
  • Lecithin:cholesterol acyltransferase
  • Proprotein convertase subtilisin/kexin 9

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. / Ruscica, Massimiliano; Simonelli, Sara; Botta, Margherita; Ossoli, Alice; Lupo, Maria Giovanna; Magni, Paolo; Corsini, Alberto; Arca, Marcello; Pisciotta, Livia; Veglia, Fabrizio; Franceschini, Guido; Ferri, Nicola; Calabresi, Laura.

In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1863, No. 9, 01.09.2018, p. 991-997.

Research output: Contribution to journalArticle

Ruscica, M, Simonelli, S, Botta, M, Ossoli, A, Lupo, MG, Magni, P, Corsini, A, Arca, M, Pisciotta, L, Veglia, F, Franceschini, G, Ferri, N & Calabresi, L 2018, 'Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders', Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol. 1863, no. 9, pp. 991-997. https://doi.org/10.1016/j.bbalip.2018.05.015
Ruscica, Massimiliano ; Simonelli, Sara ; Botta, Margherita ; Ossoli, Alice ; Lupo, Maria Giovanna ; Magni, Paolo ; Corsini, Alberto ; Arca, Marcello ; Pisciotta, Livia ; Veglia, Fabrizio ; Franceschini, Guido ; Ferri, Nicola ; Calabresi, Laura. / Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. 2018 ; Vol. 1863, No. 9. pp. 991-997.
@article{a308f6c88e0e408381b055b2a81d87ea,
title = "Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders",
abstract = "Proprotein convertase subtilisin/kexin 9 (PCSK9), a protein regulating the number of cell-surface LDL receptors (LDLR), circulates partially associated to plasma lipoproteins. How this interaction alters PCSK9 plasma levels is still unclear. In the present study, we took advantage of the availability of a large cohort of carriers of genetic HDL disorders to evaluate how HDL defects affect plasma PCSK9 levels and its distribution among lipoproteins. Plasma PCSK9 concentrations were determined by ELISA in carriers of mutations in LCAT, ABCA1, or APOAI genes, and lipoprotein distribution was analyzed by FPLC. Carriers of one or two mutations in the LCAT gene show plasma PCSK9 levels comparable to that of unaffected family controls (homozygotes, 159.4 ng/mL (124.9;243.3); heterozygotes, 180.3 ng/mL (127.6;251.5) and controls, 190.4 ng/mL (146.7;264.4); P for trend = 0.33). Measurement of PCSK9 in plasma of subjects carrying mutations in ABCA1 or APOAI genes confirmed normal values. When fractionated by FPLC, PCSK9 peaked in a region between LDL and HDL in control subjects. In carriers of all HDL defects, lipoprotein profile shows a strong reduction of HDL, but the distribution of PCSK9 was superimposable to that of controls. In conclusion, the present study demonstrates that in genetically determined low HDL states plasma PCSK9 concentrations and lipoprotein distribution are preserved, thus suggesting that HDL may not be involved in PCSK9 transport in plasma.",
keywords = "Genetic HDL disorders, High-density lipoproteins, Lecithin:cholesterol acyltransferase, Proprotein convertase subtilisin/kexin 9",
author = "Massimiliano Ruscica and Sara Simonelli and Margherita Botta and Alice Ossoli and Lupo, {Maria Giovanna} and Paolo Magni and Alberto Corsini and Marcello Arca and Livia Pisciotta and Fabrizio Veglia and Guido Franceschini and Nicola Ferri and Laura Calabresi",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.bbalip.2018.05.015",
language = "English",
volume = "1863",
pages = "991--997",
journal = "Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids",
issn = "1388-1981",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders

AU - Ruscica, Massimiliano

AU - Simonelli, Sara

AU - Botta, Margherita

AU - Ossoli, Alice

AU - Lupo, Maria Giovanna

AU - Magni, Paolo

AU - Corsini, Alberto

AU - Arca, Marcello

AU - Pisciotta, Livia

AU - Veglia, Fabrizio

AU - Franceschini, Guido

AU - Ferri, Nicola

AU - Calabresi, Laura

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Proprotein convertase subtilisin/kexin 9 (PCSK9), a protein regulating the number of cell-surface LDL receptors (LDLR), circulates partially associated to plasma lipoproteins. How this interaction alters PCSK9 plasma levels is still unclear. In the present study, we took advantage of the availability of a large cohort of carriers of genetic HDL disorders to evaluate how HDL defects affect plasma PCSK9 levels and its distribution among lipoproteins. Plasma PCSK9 concentrations were determined by ELISA in carriers of mutations in LCAT, ABCA1, or APOAI genes, and lipoprotein distribution was analyzed by FPLC. Carriers of one or two mutations in the LCAT gene show plasma PCSK9 levels comparable to that of unaffected family controls (homozygotes, 159.4 ng/mL (124.9;243.3); heterozygotes, 180.3 ng/mL (127.6;251.5) and controls, 190.4 ng/mL (146.7;264.4); P for trend = 0.33). Measurement of PCSK9 in plasma of subjects carrying mutations in ABCA1 or APOAI genes confirmed normal values. When fractionated by FPLC, PCSK9 peaked in a region between LDL and HDL in control subjects. In carriers of all HDL defects, lipoprotein profile shows a strong reduction of HDL, but the distribution of PCSK9 was superimposable to that of controls. In conclusion, the present study demonstrates that in genetically determined low HDL states plasma PCSK9 concentrations and lipoprotein distribution are preserved, thus suggesting that HDL may not be involved in PCSK9 transport in plasma.

AB - Proprotein convertase subtilisin/kexin 9 (PCSK9), a protein regulating the number of cell-surface LDL receptors (LDLR), circulates partially associated to plasma lipoproteins. How this interaction alters PCSK9 plasma levels is still unclear. In the present study, we took advantage of the availability of a large cohort of carriers of genetic HDL disorders to evaluate how HDL defects affect plasma PCSK9 levels and its distribution among lipoproteins. Plasma PCSK9 concentrations were determined by ELISA in carriers of mutations in LCAT, ABCA1, or APOAI genes, and lipoprotein distribution was analyzed by FPLC. Carriers of one or two mutations in the LCAT gene show plasma PCSK9 levels comparable to that of unaffected family controls (homozygotes, 159.4 ng/mL (124.9;243.3); heterozygotes, 180.3 ng/mL (127.6;251.5) and controls, 190.4 ng/mL (146.7;264.4); P for trend = 0.33). Measurement of PCSK9 in plasma of subjects carrying mutations in ABCA1 or APOAI genes confirmed normal values. When fractionated by FPLC, PCSK9 peaked in a region between LDL and HDL in control subjects. In carriers of all HDL defects, lipoprotein profile shows a strong reduction of HDL, but the distribution of PCSK9 was superimposable to that of controls. In conclusion, the present study demonstrates that in genetically determined low HDL states plasma PCSK9 concentrations and lipoprotein distribution are preserved, thus suggesting that HDL may not be involved in PCSK9 transport in plasma.

KW - Genetic HDL disorders

KW - High-density lipoproteins

KW - Lecithin:cholesterol acyltransferase

KW - Proprotein convertase subtilisin/kexin 9

UR - http://www.scopus.com/inward/record.url?scp=85047825627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047825627&partnerID=8YFLogxK

U2 - 10.1016/j.bbalip.2018.05.015

DO - 10.1016/j.bbalip.2018.05.015

M3 - Article

AN - SCOPUS:85047825627

VL - 1863

SP - 991

EP - 997

JO - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

JF - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

SN - 1388-1981

IS - 9

ER -